Terray Therapeutics Secures $120M in Series B Funding to Revolutionize Small Molecule Drug Development with Advanced AI

Los Angeles, CA, October 17, 2024  (Business Wire) -- Terray Therapeutics has successfully raised $120 million in Series B funding to advance its innovative approach to small molecule drug development. This investment, led by Bedford Ridge Capital and existing investor NVentures, will enhance Terray's AI platform, tNova, and propel its internal programs into clinical trials. The company boasts the world's largest chemistry dataset, having measured over 5 billion target-ligand interactions, which significantly enhances its capabilities in drug discovery.

Read full article here.